A Sherbrooke-based company, Immune Biosolutions, says it has developed a biological drug candidate that is “capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern that have emerged throughout the pandemic, including the latest Omicron variant.”
IBIO123, the company says in a statement , is an inhaled antibody-based immunotherapy undergoing Phase 1 and 2 clinical trials to test effectiveness and safety among those with mild to moderate symptoms. Results are expected in the first and third quarters of 2022, respectively. A similar study with hospitalized patients is expected to begin soon.
The company said it is looking for a strategic partner to work with on development of its therapy and “for the establishment of a global commercialization strategy.”